Rep. Robert B. Aderholt

Maddy summaryThe PORCUPINE Act amends the Arms Export Control Act to include Taiwan alongside New Zealand and Israel in specific certification and reporting requirements related to U.S. arms exports. This legislative change ensures Taiwan is treated similarly to these allied nations in certain foreign policy contexts involving defense article transfers. The bill also directs the Secretary of State to assess the feasibility of creating an expedited licensing process for military equipment transfers from designated allies to Taiwan within 90 days. Additionally, the act requires biennial reports on the implementation of these amendments and includes a provision stating that the legislation does not alter existing U.S. policy toward Taiwan under the Taiwan Relations Act. The entire measure is set to expire seven years after its enactment.

Maddy summaryHR 909, the Crime Victims Fund Stabilization Act of 2025, modifies how funds from the False Claims Act are deposited into the Crime Victims Fund. It specifies that from 2025 through 2029, certain False Claims Act proceeds (specifically those for qui tam plaintiff payments and government damage reimbursements) cannot be deposited into the fund. This change directly affects the composition of the Crime Victims Fund by excluding these specific revenue streams during the specified period. The bill does not create new benefits or alter victim services; it only adjusts fund allocation rules for existing False Claims Act revenues.

Maddy summaryThis House resolution (HRES 952) expresses the U.S. House of Representatives' support for Gibraltar's right to determine its own political status as a British Overseas Territory through self-determination. It recognizes Gibraltar's democratic choices - where over 98% of voters chose to remain under British sovereignty in 1967 and 2002 - and highlights Gibraltar's historical role in U.S. military operations, including World War II and NATO missions. The resolution affirms that Gibraltarians' views must be central to any discussions about Gibraltar's future status, while acknowledging the territory's strategic importance to U.S. security interests in the Mediterranean. As a non-binding resolution, it does not alter U.S. policy but formally honors Gibraltar's contributions and right to self-determination under international law.

Essential Caregivers Act of 2025   This bill prohibits certain health care facilities from limiting the access of essential caregivers to residents of those facilities, including during designated emergency periods.   Specifically, the bill generally prohibits Medicare skilled nursing facilities, Medicaid nursing facilities, Medicaid intermediate care facilities, and associated inpatient rehabilitation facilities from restricting the access of essential caregivers to residents of the facilities, including during emergency periods in which visitation rights are otherwise restricted. During emergency periods, facilities may restrict access for an initial period of up to seven days and for one additional maximum seven-day period (if the additional period is approved by the state health department). Facilities may restrict access for a total of 7 days (or 14 days with the approval of the state health department) during an emergency period. Essential caregivers must agree to comply with any safety protocols set by the facility, which may be no more stringent for caregivers compared to those for staff. Caregivers who fail to comply with these requirements may be denied access, subject to an appeals process.

Maddy summaryThis bill establishes new requirements for pharmacy benefit managers (PBMs) working with Medicare Part D prescription drug plans and Medicaid programs. It mandates that PBMs pay pharmacies a specific reimbursement amount based on drug acquisition costs plus a fixed fee, pass through manufacturer rebates directly to beneficiaries at the point of sale, and prohibits steering practices that direct patients to specific pharmacies. The bill applies to Medicare Part D plans and Medicaid managed care organizations beginning January 1, 2027, affecting how PBMs interact with pharmacies and handle drug rebates. Violations could result in criminal penalties of up to $1 million or 10 years in prison for willful noncompliance. The bill aims to increase transparency and fairness in pharmacy drug pricing for Medicare and Medicaid beneficiaries.

Maddy summaryHR 1623 (the SCREEN Act) requires online platforms that profit from hosting pornographic content to implement age verification technology, preventing minors from accessing such material. Covered platforms must publicly disclose their verification process and securely handle age data collected through these systems. The law applies specifically to platforms where pornographic content is a regular business activity, not all websites. It mandates that only adults can access pornographic content on these platforms, without banning the content itself.

Maddy summaryHR 6540, the "Anti-Communism Week Act," designates an annual observance to commemorate historical impacts of communist regimes. The bill requests the President to annually designate a week as "Anti-Communism Week" and issue a proclamation encouraging public ceremonies. It does not create new policies or affect specific groups; it only adds a procedural requirement to the U.S. Code for an annual presidential designation. The bill focuses on commemoration, not policy change, and references historical findings about communism in its preamble.

Maddy summaryHR 6466, the Forced Abortion Prevention and Accountability Act, prohibits non-consensual administration of abortion drugs (like mifepristone or misoprostol) to pregnant women without their informed consent. It criminalizes this act with penalties up to 25 years in prison and allows victims to sue for triple damages, psychological/physical injury compensation, and attorney fees. The bill directly affects pregnant women who might face coerced procedures and medical providers or others who administer such drugs without consent. Key provisions include criminal penalties for the act itself, enhanced penalties for serious injury or death, and a civil remedy framework for victims seeking compensation.

Maddy summaryHJRES 133 is a joint resolution requesting the Secretary of the Interior to authorize temporary displays on the National Mall and Washington Monument during December 31, 2025, to January 5, 2026. It specifically asks for five nights of public displays featuring semiquincentennial materials, artifacts, and projected content onto the Washington Monument. The resolution aims to commemorate the 250th anniversary of U.S. independence, building on past celebrations like the 1976 bicentennial and 2019 Apollo 11 commemoration. This request affects the Secretary of the Interior (who would grant authorization) and the public (who would attend the displays).

Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.  Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research.  The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)